Thermo Fisher Scientific (TMO) – Acquisition of Brammer Bio will boost growth for TMO

in on June 19, 2019

TMO completed the acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for ~$1.7bn in cash. Brammer will become part of TMO’s Pharma Services business within its Laboratory Products and Services Segment. This acquisition will boost growth for the company and therefore, we expect 4% growth in revenues in FY19 and 7% growth in revenues in FY20.

Number of Pages – 38

Contents

Executive Summary

Financial Statements

–Income Statement and Forecast

–Balance Sheet

–Cash Flow

–Q1FY19 Results – Overview

–Q1FY19 – Segment Performance

–FY19 Guidance

–Conclusion

–GAAP to Non-GAAP Reconciliation

Historical Performance

–Key Ratios

–Profitability Ratios, Asset Turnover Ratio, Growth Ratio

–Per Share Items and Key Ratios

–Key Balance Sheet and Cash Flow Items

–P/E Band

Product Performance and Key Developments

–Ownership

–Competitors

–Key Developments

Valuation and Consensus Performance

–Relative Valuation

–Analyst Recommendations

Market Price Performance

CrispIdea Coverage

Release Information

  • Released
    :

    June 19, 2019

  • Last Updated
    :

    June 27, 2019